Doctor Michel Zeitouni

Back

Doctor Michel Zeitouni

Pitie Salpetriere APHP University Hospital, Paris (France)

Presentations

Levosimendan in patients with cardiogenic shock refractory to dobutamine weaning

Event: ESC Congress 2024

Topic: Cardiogenic Shock

Session: New insights into pharmacotherapy for acute heart failure

Access

Early versus delayed introduction of renin angiotensin aldosterone system inhibitors in cardiogenic shock

Event: ESC Congress 2023

Topic: Pharmacotherapy

Session: Acute heart failure: prevention and treatment

Access

Have the ESC guidelines improved the identification and prevention of individuals at risk of premature myocardial infarction?

Event: ESC Congress 2022

Topic: Scores

Session: Cardiovascular risk assessment - Scores 1

Access

Causes and predictors of short, intermediate and long-term mortality in patients after PCI

Event: ESC Congress 2019

Topic: Epidemiology, Prognosis, Outcome

Session: Long term prognosis in coronary artery disease

Access

Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE

Event: ESC Congress 2019

Topic: Oral Anticoagulation

Session: Atrial fibrillation and oral anticoagulation 1

Access

Investigator versus Core Lab evaluation of coronary blood flow in PCI of patients in cardiogenic shock: a substudy of the CULPRIT-SHOCK trial.

Event: ESC Congress 2019

Topic: Coronary Angiography

Session: High risk percutaneous coronary intervention: STEMI, CTO, atherectomy bifurcations shock

Access

Intima-Media thickness to better risk-stratify patients with premature coronary artery disease: an analysis from the AFUI registry.

Event: ESC Congress 2018

Topic: Imaging

Session: Secondary prevention

Access

Professional status and long-term prognosis of premature coronary artery disease: the AFIJI registry.

Event: ESC Congress 2018

Topic: Stress, Psychosocial and Cultural Aspects of Heart Disease

Session: Stress, psycho-social and cultural aspects of heart disease and depression and heart disease

Access

The natural history of premature coronary artery disease over 20 years: the AFIJI registry.

Event: ESC Congress 2018

Topic: Epidemiology, Prognosis, Outcome

Session: Latest registry data on coronary disease outcomes

Access

Should we care about post-procedural troponin in elective coronary stenting?

Event: ESC Congress 2017

Topic: PCI: procedural complications

Session: Complications after cardiac interventions

Access

ESC 365 is supported by

Explore sponsored resources

Doctor Michel Zeitouni Follow

Contributor content

Levosimendan in patients with cardiogenic shock refractory to dobutamine weaning

Early versus delayed introduction of renin angiotensin aldosterone system inhibitors in cardiogenic shock

Have the ESC guidelines improved the identification and prevention of individuals at risk of premature myocardial infarction?

Causes and predictors of short, intermediate and long-term mortality in patients after PCI

Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE

Investigator versus Core Lab evaluation of coronary blood flow in PCI of patients in cardiogenic shock: a substudy of the CULPRIT-SHOCK trial.

Intima-Media thickness to better risk-stratify patients with premature coronary artery disease: an analysis from the AFUI registry.

Professional status and long-term prognosis of premature coronary artery disease: the AFIJI registry.

The natural history of premature coronary artery disease over 20 years: the AFIJI registry.

Should we care about post-procedural troponin in elective coronary stenting?

ESC 365 is supported by

Doctor Michel Zeitouni